What is BacterioScan?
BacterioScan offers a groundbreaking, FDA-cleared device for rapid and accurate UTI detection. Leveraging advanced light scattering technology, the device provides diagnostic results within 30 to 180 minutes, boasting a 97.7% sensitivity and a 99.2% negative predictive value. This technology is pivotal for improving antibiotic stewardship by enabling healthcare providers to quickly identify true-negative UTI cases, thereby reducing the incidence of unnecessary antibiotic prescriptions and mitigating associated healthcare costs. The company's solution directly addresses the inefficiencies and expenses linked to traditional UTI testing methods.
How much funding has BacterioScan raised?
BacterioScan has raised a total of $9.9M across 4 funding rounds:
Unspecified
$2.1M
Series A
$6M
Unspecified
$1.7M
Debt
$150K
Unspecified (2013): $2.1M, investors not publicly disclosed
Series A (2014): $6M led by Warson Capital Partners, BioGenerator, and Missouri Technology
Unspecified (2015): $1.7M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Key Investors in BacterioScan
Warson Capital Partners
Warson Capital Partners is a St. Louis-based firm specializing in capital sourcing, mergers and acquisitions, and financial restructuring. With over 20 years of experience, they provide exceptional services to emerging middle-market companies, helping them secure efficient debt and equity capital.
BioGenerator
Based in St. Louis, Missouri, BioGenerator creates and grows innovative companies through its two complementary approaches, investing through BioGenerator Ventures and comprehensive startup support through BioGenerator Labs.
Missouri Technology
The Missouri Technology Corporation (MTC) is a public-private partnership established by the Missouri General Assembly to enhance entrepreneurship and support the development of new high-tech companies. MTC primarily targets the life sciences and technology sectors, leveraging Missouri's agricultural heritage.
What's next for BacterioScan?
With substantial enterprise-level backing, BacterioScan is poised for significant expansion and further development of its diagnostic platform. The recent strategic investment signals a commitment to scaling operations and potentially broadening its market reach. Future initiatives will likely focus on enhancing the device's capabilities, exploring new applications, and solidifying its position as a leader in point-of-care diagnostics. Continued innovation in antibiotic stewardship solutions will be key to BacterioScan's sustained growth and impact on public health.
See full BacterioScan company page
